Apollo Endosurgery

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apollo Endosurgery develops medical devices for the diagnosis and treatment of gastrointestinal diseases. The company’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon. Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.)  Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.

Grew global revenue 16% (20% in constant currency) as adoption increased across all product lines Secured FDA marketing authorization for Apollo ESGTM and Apollo REVISETM AUSTIN, TX / ACCESSWIRE / August 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2022 and recent corporate highlights. Second Quarter 2022 Selected Financial Results (Numbers in millions, except percentages) Quarter Ended June 30, 2022 Six Months Ended June 30, 2022 Revenue $ 19.3 $ 36.0 Gross margin 56.8 % 56.5 % Operating expenses $ 17.5 $ 34.2 Non-GAAP adjusted operating expenses $ 15.9 $ 31.0 Operating loss $ (6.6 ) $ (13.8 ) Net loss $ (10.4 ) $ (18.8 ) Non-GAAP adjusted EBITDA $ (4.3 ) $ (9.3 ) Cash, cash equivalents and restricted cash $ 75.7 $ 75.7 Second Quarter and Recent Corporate Highlights Grew second quarter 2022 U.S. revenue by 18% and OUS revenue by 15% (23% in constant currency) over the same period in 2021; Grew second quarter 2022 Endoscopic Suturing System (ESS) revenue 23% (27% in constant currency) over the same period in 2021; Grew second quarter 2022 Intragastric Balloon (IGB) revenue 6% (9% in constant currency) over the same period in 2021; Increased second quarter 2022 revenue from the Company's top 10 direct accounts by 53% over the same period in 2021; Received FDA De Novo marketing authorization in July 2022 for Apollo ESGTM and Apollo REVISETM, new endoscopic systems for the treatment of patients with obesity Announced publication of the MERIT Study on July 28, 2022 in The LANCET; and Appointed Sharon O'Keefe to the Board of Directors, deepening Apollo's Board-level expertise in hospital systems and health care delivery.

Apollo Endosurgery, Inc. Reports Record Global Revenue in Second Quarter 2022

Publication of MERIT Study Follows FDA Market Authorization of Apollo ESG™ AUSTIN, TX / ACCESSWIRE / July 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today the electronic publication of the landmark Multi-center ESG Randomized Interventional Trial (MERIT) Study in The Lancet.(1) The MERIT study is a multi-center, prospective randomized clinical trial evaluating the safety and effectiveness of the Endoscopic Sleeve Gastroplasty (ESG) procedure, a minimally invasive, endoscopic weight loss procedure performed with Apollo's Endosurgery's OverStitch® Endoscopic Suturing System.In the study, patients with Body Mass Index (BMI) ≥30 and ≤40 kg/m² were randomized to treatment with ESG and lifestyle modification or to a control group which involved lifestyle modification alone.

Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure

AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.

Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

Eos Energy Enterprises

TDH Hlds

Which penny stocks are you watching right now? The post Hot Penny Stocks to Watch Right Now?

Hot Penny Stocks to Watch Right Now? 3 For Your July List

Apollo Endosurgery Inc (NASDAQ: APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx Systems through the FDA De Novo Classification process. The process is a premarket review pathway for low-to moderate-risk devices.

Apollo Endosurgery's New Obesity Endoscopic Systems Receive FDA Nod

Systems Offer Effective, Minimally Invasive Treatment Options for Millions of Patients with Obesity (BMI 30-50 kg/m2) AUSTIN, TX / ACCESSWIRE / July 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today the marketing authorization of the Apollo ESGTM, Apollo ESG SxTM, Apollo REVISETM and Apollo REVISE SxTM Systems through the U.S. Food and Drug Administration's (FDA) De Novo Classification process, a rigorous pre-market review pathway for low-to moderate-risk devices without a predicate. These are the first and only devices authorized by the FDA for endoscopic sleeve gastroplasty (ESG) and endoscopic bariatric revision.

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Seasoned healthcare leader brings 30 years of hospital system and medical technology expertise AUSTIN, TX / ACCESSWIRE / July 6, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that Sharon O'Keefe has joined the company's Board of Directors, effective July 6, 2022. "We are thrilled to welcome Sharon to the Apollo Endosurgery Board," said Chas McKhann, President and CEO of Apollo.

Sharon O'Keefe Joins Apollo Endosurgery Board of Directors

AUSTIN, TX / ACCESSWIRE / May 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced highlights today from data presented at Digestive Disease Week May 21-24. "With more than 120 lectures, presentations, and posters featuring Apollo products, DDW 2022 exemplified Apollo's commitment to building a robust body of clinical evidence supporting the safe and effective use of OverStitch ® , X-Tack ® , and Orbera ® ," said Chas McKhann, President and CEO of Apollo.

Digestive Disease Week 2022 Adds to the Growing Wave of Clinical Evidence Supporting Significant Opportunity for Apollo Endosurgery Products

AUSTIN, TX / ACCESSWIRE / May 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that Apollo products and procedures that utilize Apollo products will be featured in more than 40 academic posters and videos and over 60 podium presentations and lectures at the upcoming Digestive Disease Week 2022 to be held in San Diego, May 21-24. Highlights include: Full presentation of the MERIT study of the Endoscopic Sleeve Gastroplasty (ESG) procedure's impact on obesity (Presentation 995) 5-year follow-up data for Endoscopic Sleeve Gastroplasty (Presentation 687) Endoscopic Sleeve Gastroplasty in Class III Obesity (Presentation 996) A systemic review and meta-analysis comparison of ESG and laparoscopic sleeve gastrectomy (Presentation 51) Revisional Endoscopic Sleeve Gastroplasty and GLP-1 agonist medications (Presentation 295) A multicenter study of the efficacy, feasibility and safety of the X-Tack® Endoscopic HeliX Tacking System (Presentation 388) Closure of colonic EMR defects using the X-Tack® Endoscopic HeliX Tacking System (Su1434) "Apollo Endosurgery's products and our customers have played a critical role in driving the field of therapeutic endoscopy forward, to the betterment of patient care," commented Chas McKhann, President and CEO of Apollo.

Apollo Endosurgery Products to Take Center Stage at Digestive Disease Week

Stephens has reiterated an Overweight rating for Apollo Endosurgery Inc (NASDAQ: APEN) while increasing the price target from $8 to $9. "In our opinion, APEN's valuation does not assign full value to the promising ESS business or targeted opportunities for expanded.

This Analyst Thinks Apollo Endosurgery's Valuation 'Does Not Assign Full Value' - Read Why

Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Matt Kreps - Investor Relations Chas McKhann - Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Chris Cooley - Stephens Operator Good afternoon, ladies and gentlemen, and welcome to the Apollo Endosurgery First Quarter 2022 Results Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.

Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q1 2022 Results - Earnings Call Transcript

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 0% and 6.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Apollo Endosurgery, Inc. (APEN) Reports Q1 Loss, Tops Revenue Estimates

Global revenue grew 20% year-over-year as adoption increased across all product lines AUSTIN, TX / ACCESSWIRE / May 3, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the first quarter ended March 31, 2022 and recent corporate highlights. First Quarter 2022 Selected Financial Results (Numbers in millions, except percentages) Quarter Ended March 31, 2022 Revenue $ 16.7 Gross margin 56.3 % Operating expenses $ 16.6 Non-GAAP adjusted operating expenses $ 15.1 Operating loss $ (7.2 ) Net loss $ (8.4 ) Non-GAAP adjusted EBITDA $ (5.0 ) Cash, cash equivalents and restricted cash $ 82.7 First Quarter and Corporate Highlights Grew first quarter 2022 Endoscopic Suturing System (ESS) revenue 24% over the same period in 2021; Grew first quarter 2022 Intragastric Balloon (IGB) revenue 16% over the same period in 2021; Increased first quarter 2022 revenue from the Company's top 10 direct accounts by 63% over the same period in 2021; Appointed Jeannette Bankes to Board of Directors, deepening Apollo Endosurgery's Board-level expertise in developing and commercializing new medical technologies.

Apollo Endosurgery, Inc. Reports 33% U.S. Revenue Growth in First Quarter 2022

AUSTIN, TX / ACCESSWIRE / April 13, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (Nasdaq:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the first quarter ended March 31, 2022 on Tuesday, May 3, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.

Apollo Endosurgery to Report First Quarter Results on May 3, 2022

Veteran Brings 30 Years of Multinational Healthcare Leadership Experience AUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the Global Surgical Franchise at Alcon, a worldwide developer, manufacturer and marketer of eye care medical devices and ophthalmic products.

Apollo Endosurgery Appoints Jeannette Bankes to Board of Directors

AUSTIN, TX / ACCESSWIRE / March 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that Chas McKhann, CEO, and Jeff Black, CFO, will host investor meetings March 7-8, 2022 as part of the Cowen Healthcare Conference, taking place virtually. As part of the conference event, management will participate in a fireside chat hosted by Cowen at 12:50 pm Eastern Time on Monday, March 7, 2022.

Apollo Endosurgery to Participate in the Cowen Healthcare Conference

Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q4 2021 Results - Earnings Call Transcript

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -35% and 0.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Apollo Endosurgery, Inc. (APEN) Reports Q4 Loss, Tops Revenue Estimates

Increased adoption across all product lines in both U.S. and international Grew fourth quarter 2021 revenue 26% AUSTIN, TX / ACCESSWIRE / February 22, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the fourth quarter and year ended December 31, 2021 and corporate highlights. Fourth Quarter and Full Year 2021 Selected Financial Results (Numbers in millions, except percentages) Quarter Ended December 31, 2021 Year Ended December 31, 2021 Revenue $ 16.2 $ 63.0 Gross margin 56.3 % 55.5 % Operating expenses $ 14.8 $ 54.2 Non-GAAP adjusted operating expenses $ 13.3 $ 47.9 Operating loss $ (5.7 ) $ (19.2 ) Non-GAAP adjusted EBITDA $ (3.5 ) $ (9.9 ) Cash, cash equivalents and restricted cash $ 91.8 Fourth Quarter and Full Year Financial and Corporate Highlights Grew fourth quarter 2021 and full year Endoscopic Suturing System (ESS) revenue 37% and 55% over the same periods in 2020; Grew fourth quarter 2021 and full year Intragastric Balloon (IGB) revenue 20% and 50% over the same periods of 2020; Increased fourth quarter 2021 and full year revenue from the Company's top 10 direct accounts by over 50% and 85% over the same periods in 2020; Continued X-Tack penetration in key accounts, with fourth quarter 2021 revenue growth of nearly 40% and an increase in ordering customers of nearly 20% compared to the third quarter 2021; Secured over $175 million in new capital and borrowing capacity, providing cash runway to fund Apollo's planned growth initiatives; Announced that investigators in the Multi-Center ESG Randomized Interventional (MERIT) study reported that the study met its primary endpoints for safety and efficacy.

Apollo Endosurgery, Inc. Reports 50% Revenue Growth in 2021

Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Apollo Endosurgery, Inc. (APEN) Q4 Earnings Expected to Decline

AUSTIN, TX / ACCESSWIRE / February 10, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the fourth quarter and full year ended December 31, 2021 on Tuesday, February 22, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.

Apollo Endosurgery to Report Fourth Quarter and Full Year Results on February 22, 2022

Veteran Leader Brings 25 Years of Global Medical Device Experience AUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022. "At Apollo, we are addressing large unmet clinical needs in both gastroenterology and weight loss.

Apollo Endosurgery Appoints Keely Scamperle as Vice President of Reimbursement and Market Access

Apollo Endosurgery, Inc. (APEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 21.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Apollo Endosurgery, Inc. (APEN)

Fourth quarter 2021 revenue grew 25% over 2020 AUSTIN, TX / ACCESSWIRE / January 10, 2022 / Apollo Endosurgery, Inc. ("Apollo" or the "Company") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2021. Preliminary, Unaudited 2021 Revenue Quarter Ended December 31, 2021 Year Ended December 31, 2021 Total revenue $16.1 million to $16.3 million $62.9 million to $63.1 million Preliminary, unaudited full year 2021 revenue increased approximately 50% compared to 2020.

Apollo Endosurgery Announces Preliminary 2021 Revenue Results; Reflecting 50% Growth Over 2020

Apollo Endosurgery, Inc. (APEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Apollo Endosurgery Stock (APEN)